FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

WILSON TROY EDWARD
2. Issuer Name and Ticker or Trading Symbol

Kura Oncology, Inc. [ KURA ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President and CEO
(Last)          (First)          (Middle)

C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400
3. Date of Earliest Transaction (MM/DD/YYYY)

9/8/2020
(Street)

SAN DIEGO, CA 92130
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 9/8/2020  S(1)  50000 D$26.00 306736 I by Araxes Pharma LLC 
Common Stock 9/10/2020  S(1)  1025 D$28.00 305711 I by Araxes Pharma LLC 
Common Stock 9/10/2020  M(2)  37030 A$6.15 65126 D  
Common Stock 9/10/2020  S(2)  37030 D$28.00 28096 D  
Common Stock         1795017 I by Red Fish Blue Fish Revocable Trust 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to purchase common stock $6.15 9/10/2020  M (2)    37030   (3)1/22/2027 Common Stock 37030 $0.00 174947 D  

Explanation of Responses:
(1) This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020.
(2) The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020.
(3) This option vests in 48 equal monthly installments commencing on January 23, 2017.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
WILSON TROY EDWARD
C/O KURA ONCOLOGY, INC.
12730 HIGH BLUFF DRIVE, SUITE 400
SAN DIEGO, CA 92130
X
President and CEO

Signatures
James Basta, Attorney-in-fact for Troy E. Wilson9/10/2020
**Signature of Reporting PersonDate

Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Kura Oncology Charts.
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Kura Oncology Charts.